SCF ENCYCLOPEDIA ENTRY

POSTPARTUM PREECLAMPSIA

SCF-RDOS Registry Code: SCF-RDOS-PPD-HT-001

Disease Type Classification: Hypertensive Disorder → Postpartum Vascular-Endothelial Disease → Postpartum Preeclampsia Syndrome

Adaptive Module Activation:

• Universal Core Module
• Cardiovascular Disease Expansion
• Endothelial Dysfunction Expansion
• Neurovascular Disease Expansion
• Renal Disease Expansion
• Immunovascular Expansion
• Multiorgan Perfusion Expansion

1. SCOPE & POSITIONING

Etiology / Classification

Postpartum Preeclampsia is a hypertensive multisystem disorder that develops after childbirth, typically within the first 48 hours postpartum but potentially occurring up to 6 weeks following delivery.

The condition is characterized by:

• New-onset hypertension postpartum
• Endothelial dysfunction
• Multisystem vascular injury
• Organ-specific manifestations
• Increased maternal morbidity and mortality

Unlike antepartum preeclampsia, postpartum preeclampsia develops after delivery, often when both patient and healthcare providers expect physiologic recovery to occur.

Within the SCF framework, Postpartum Preeclampsia is classified as:

A postpartum endothelial-neurovascular dysregulation syndrome characterized by persistence or delayed emergence of systemic vascular injury, inflammatory endothelial activation, maladaptive maternal hemodynamics, and multiorgan microvascular dysfunction following childbirth.

SCF Classification

SCF Disease Category: Postpartum Endothelial Regulatory Failure Syndrome

SCF Functional Class:

Maternal Neurovascular-Endothelial Dysfunction Disorder

SCF Fault Tier Classification

Clinical Significance

Postpartum Preeclampsia represents one of the leading causes of postpartum maternal readmission and severe maternal morbidity.

Potential complications include:

• Eclampsia
• Intracranial hemorrhage
• Ischemic stroke
• Posterior reversible encephalopathy syndrome (PRES)
• Pulmonary edema
• Acute kidney injury
• Heart failure
• Myocardial injury
• Hepatic dysfunction
• Maternal death

SCF Domain Alignment

Primary Domains:

• Cardiovascular
• Endothelial
• Neurovascular
• Renal

Secondary Domains:

• Immune
• Hepatic
• Pulmonary
• Hematologic

2. ETIOPATHOGENIC CORE

Primary Cause

Postpartum Preeclampsia develops through persistent or delayed activation of endothelial injury pathways that remain active after delivery despite removal of the placenta.

The disease reflects incomplete resolution of pregnancy-associated vascular dysfunction and ongoing maladaptation of maternal cardiovascular regulatory systems.

Key Drivers

Driver A — Persistent Endothelial Dysfunction

Endothelial injury remains active through:

• Reduced nitric oxide bioavailability
• Increased vascular permeability
• Proinflammatory signaling
• Vasoconstrictive predominance

Result:

• Hypertension and organ injury

Driver B — Antiangiogenic Imbalance

Persistent dysregulation of:

• sFlt-1
• VEGF
• PlGF

Results in:

• Endothelial instability
• Impaired vascular repair

Driver C — Neurovascular Dysregulation

Abnormal cerebral vascular control causes:

• Vasospasm
• Hyperperfusion injury
• Cerebral edema

Result:

• Severe headaches
• Seizures
• PRES

Driver D — Renal Endothelial Injury

Glomerular endothelial dysfunction causes:

• Proteinuria
• Sodium retention
• Volume dysregulation

Result:

• Hypertension amplification

Driver E — Immunovascular Activation

Persistent activation of:

• Cytokine pathways
• Complement systems
• Endothelial inflammatory networks

Result:

• Progressive vascular injury

3. SCF FAULT ARCHITECTURE

4. PATHOGENESIS FLOW (SCF LOGIC)

Pregnancy-Associated Endothelial Activation

↓

Delivery

↓

Expected Vascular Resolution

↓

Failure of Endothelial Recovery

↓

Persistent Antiangiogenic Signaling

↓

Systemic Vasoconstriction

↓

Microvascular Dysfunction

↓

Hypertension

↓

Renal Injury

↓

Neurovascular Injury

↓

Cardiovascular Stress

↓

Multiorgan Endothelial Disease

↓

Postpartum Preeclampsia

↓

Eclampsia and Severe Maternal Complications

5. CLINICAL SPECTRUM

6. SCF TRINITY FRAMEWORK MAPPING

Trinity Axis I — Structural Integrity

Affected Systems:

• Endothelium
• Renal glomeruli
• Cerebral vasculature
• Pulmonary microvasculature

Primary Failure:

• Microvascular structural dysfunction

Trinity Axis II — Energetic Integrity

Affected Systems:

• Mitochondrial endothelial function
• Organ oxygen delivery systems
• Cellular metabolic regulation

Primary Failure:

• Endothelial bioenergetic stress

Trinity Axis III — Informational Integrity

Affected Systems:

• Angiogenic signaling
• Neurovascular regulation
• Endocrine-hemodynamic control systems

Primary Failure:

• Vascular signaling desynchronization

7. HYPERTENSIVE DISORDER EXPANSION MODULE

Clinical Subtype Registry

Type A

De Novo Postpartum Preeclampsia

Characteristics:

• New-onset disease after delivery
• No antepartum preeclampsia history

Type B

Persistent Preeclampsia Syndrome

Characteristics:

• Continuation of antepartum disease
• Incomplete postpartum resolution

Type C

Neurovascular-Dominant Postpartum Preeclampsia

Characteristics:

• Severe headaches
• Visual disturbances
• PRES risk

Type D

Cardiopulmonary Postpartum Preeclampsia

Characteristics:

• Pulmonary edema
• Heart failure
• Severe hypertension

Type E

Atypical Postpartum Preeclampsia

Characteristics:

• Organ dysfunction without classic presentation
• Delayed diagnosis risk

8. MULTI-OMICS PATHOGENESIS MAP

9. SCF PCR THERAPEUTIC STRATEGY

PREVENTATIVE

Objectives

Prevent progression from postpartum hypertension to severe multisystem disease.

Targets:

• Endothelial injury
• Neurovascular instability
• Renal dysfunction
• Hypertensive escalation

CURATIVE

Objectives

Control blood pressure and prevent end-organ injury.

Targets:

• Severe hypertension
• Endothelial dysfunction
• Cerebral complications
• Pulmonary edema

Interventions:

• Antihypertensive therapy
• Magnesium sulfate seizure prophylaxis
• Fluid management
• Intensive maternal monitoring

RESTORATIVE

Objectives

Restore vascular integrity and long-term cardiovascular resilience.

Targets:

• Endothelial repair
• Microvascular recovery
• Renal restoration
• Cardiovascular normalization

Potential strategies:

• SCF-derived endothelial restorative platforms
• Precision angiogenic recalibration systems
• Neurovascular protection therapeutics
• Long-term cardiovascular risk reduction programs

10. CURRENT STANDARD OF CARE

Diagnostic Evaluation

Clinical Assessment

• Blood pressure monitoring
• Neurologic examination
• Pulmonary assessment
• Fluid status evaluation

Laboratory Evaluation

• Complete blood count
• Liver function tests
• Renal function tests
• Urine protein assessment
• Lactate dehydrogenase

Imaging

When clinically indicated:

• Brain MRI
• Brain CT
• Echocardiography
• Chest imaging

Treatment

Blood Pressure Control

Common therapeutic classes:

• Intravenous antihypertensives for severe disease
• Oral antihypertensive therapy for stabilization

Seizure Prevention

• Magnesium sulfate

Critical Care

For severe disease:

• ICU monitoring
• Respiratory support
• Organ-specific management

11. SCF THERAPEUTIC ENGINEERING OPPORTUNITIES

SCF Target Cluster A

Endothelial Restoration Platform

Targets:

• Nitric oxide signaling
• Endothelial repair pathways
• Barrier integrity

SCF Target Cluster B

Angiogenic Rebalancing Platform

Targets:

• sFlt-1 modulation
• VEGF signaling
• PlGF restoration

SCF Target Cluster C

Neurovascular Protection Platform

Targets:

• Cerebral autoregulation
• Blood-brain barrier stability
• Seizure prevention pathways

SCF Target Cluster D

Cardiovascular Recovery Platform

Targets:

• Vascular compliance
• Cardiac remodeling
• Long-term cardiovascular resilience

12. TRANSLATIONAL BLUEPRINT

Diagnostic Biomarkers

Angiogenic

• sFlt-1
• PlGF
• sFlt-1/PlGF ratio

Endothelial

• Endothelin-1
• von Willebrand factor
• Soluble thrombomodulin

Renal

• Creatinine
• Urine protein-creatinine ratio
• Cystatin C

Cardiovascular

• BNP
• NT-proBNP
• Cardiac troponins

Clinical Endpoints

Primary:

• Blood pressure normalization

Secondary:

• Prevention of eclampsia
• Resolution of endothelial dysfunction
• Preservation of renal function
• Reduction of cardiovascular complications

FDA Translational Pathway

Preclinical

↓

IND

↓

Phase I Safety

↓

Phase II Endothelial Recovery Proof-of-Concept

↓

Phase III Maternal Outcome Trials

↓

NDA/BLA Submission

13. SCF DBI INTERPRETATION

Decentralized Biological Intelligence Failure

Cellular Layer

Endothelial cells remain locked in an activated injury phenotype rather than transitioning to postpartum recovery.

Tissue Layer

Microvascular networks fail to restore normal vascular tone and permeability regulation.

Organ Layer

Kidneys, brain, heart, and lungs experience persistent endothelial-mediated dysfunction.

System Layer

Cardiovascular, neurovascular, immune, and endocrine recovery systems become desynchronized after delivery.

Whole-Organism Layer

Maternal physiology fails to complete the transition from pregnancy-associated vascular adaptation to normal postpartum homeostasis, resulting in systemic hypertensive disease.

14. SCF LAYMAN’S SUMMARY

Postpartum Preeclampsia is a serious condition that develops after childbirth and causes high blood pressure along with injury to blood vessels and organs throughout the body.

According to the SCF model, the disease occurs when the blood vessels fail to recover normally after pregnancy. Instead of returning to a healthy state, the vascular system remains inflamed, constricted, and dysfunctional. This can affect the brain, kidneys, lungs, heart, and liver.

Common symptoms include:

• Severe headache
• High blood pressure
• Vision changes
• Swelling
• Shortness of breath
• Chest discomfort
• Nausea
• Reduced urine output

Postpartum Preeclampsia can occur even in women who had normal blood pressure during pregnancy. Early recognition and treatment are essential because the condition can rapidly progress to seizures, stroke, organ failure, or death.

SCF-RDOS INDICATION SUMMARY